JP5395664B2 - 融合ペプチド治療用組成物 - Google Patents

融合ペプチド治療用組成物 Download PDF

Info

Publication number
JP5395664B2
JP5395664B2 JP2009527565A JP2009527565A JP5395664B2 JP 5395664 B2 JP5395664 B2 JP 5395664B2 JP 2009527565 A JP2009527565 A JP 2009527565A JP 2009527565 A JP2009527565 A JP 2009527565A JP 5395664 B2 JP5395664 B2 JP 5395664B2
Authority
JP
Japan
Prior art keywords
elp
protein
elp1
thioredoxin
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009527565A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010502734A (ja
JP2010502734A5 (OSRAM
Inventor
チルコティ，アシュトシュ
Original Assignee
フェーズバイオ ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フェーズバイオ ファーマシューティカルズ，インコーポレイテッド filed Critical フェーズバイオ ファーマシューティカルズ，インコーポレイテッド
Publication of JP2010502734A publication Critical patent/JP2010502734A/ja
Publication of JP2010502734A5 publication Critical patent/JP2010502734A5/ja
Application granted granted Critical
Publication of JP5395664B2 publication Critical patent/JP5395664B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2009527565A 2006-09-06 2007-09-06 融合ペプチド治療用組成物 Active JP5395664B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84246406P 2006-09-06 2006-09-06
US60/842,464 2006-09-06
PCT/US2007/077767 WO2008030968A2 (en) 2006-09-06 2007-09-06 Fusion peptide therapeutic compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013217181A Division JP5802250B2 (ja) 2006-09-06 2013-10-18 融合ペプチド治療用組成物

Publications (3)

Publication Number Publication Date
JP2010502734A JP2010502734A (ja) 2010-01-28
JP2010502734A5 JP2010502734A5 (OSRAM) 2010-10-14
JP5395664B2 true JP5395664B2 (ja) 2014-01-22

Family

ID=39158053

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009527565A Active JP5395664B2 (ja) 2006-09-06 2007-09-06 融合ペプチド治療用組成物
JP2013217181A Active JP5802250B2 (ja) 2006-09-06 2013-10-18 融合ペプチド治療用組成物
JP2015168457A Pending JP2016026167A (ja) 2006-09-06 2015-08-28 融合ペプチド治療用組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013217181A Active JP5802250B2 (ja) 2006-09-06 2013-10-18 融合ペプチド治療用組成物
JP2015168457A Pending JP2016026167A (ja) 2006-09-06 2015-08-28 融合ペプチド治療用組成物

Country Status (9)

Country Link
US (3) US20110039776A1 (OSRAM)
EP (1) EP2059606A4 (OSRAM)
JP (3) JP5395664B2 (OSRAM)
CN (2) CN101578373A (OSRAM)
AU (1) AU2007292295B2 (OSRAM)
CA (1) CA2663047A1 (OSRAM)
IL (2) IL197442A (OSRAM)
MX (1) MX2009002547A (OSRAM)
WO (1) WO2008030968A2 (OSRAM)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170107352A (ko) * 2016-03-14 2017-09-25 한양대학교 에리카산학협력단 상 전이 거동을 가지는 폴리펩타이드, 상기 폴리펩타이드-칼모듈린-폴리펩타이드의 다중-자극 반응성을 가지는 삼중 블럭 폴리펩타이드, 상기 삼중 블럭 폴리펩타이드로 제조된 하이드로젤 및 상기 하이드로젤의 용도
KR20170114251A (ko) * 2016-03-24 2017-10-13 한양대학교 에리카산학협력단 지능형 약물 전달을 위한 다중 자극 반응성을 지닌 칼모듈린-엘라스틴 이중 블럭 폴리펩타이드의 동적 나노 전달체 및 제조방법
KR20220026515A (ko) * 2020-08-25 2022-03-04 한양대학교 에리카산학협력단 자극 반응성 및 표면 부착성을 가진 점착성 엘라스틴 및 서커린 기반 다중 블록 코폴리펩타이드, 그의 자가조립 구조체 및 주사형 하이드로겔의 생접착제 응용

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007016271A2 (en) * 2005-07-28 2007-02-08 Global Research Technologies, Llc Removal of carbon dioxide from air
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) * 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US8334257B2 (en) 2005-12-20 2012-12-18 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US7709227B2 (en) 2006-01-04 2010-05-04 Phasebio Pharmaceuticals, Inc. Multimeric ELP fusion constructs
EP2327768B1 (en) 2006-04-03 2015-09-09 Promega Corporation Permuted and nonpermuted luciferase biosensors
JP6110591B2 (ja) 2008-05-19 2017-04-05 プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ ｃＡＭＰのためのルシフェラーゼバイオセンサー
CA2726894A1 (en) 2008-06-27 2009-12-30 Duke University Therapeutic agents comprising elastin-like peptides
WO2010004273A1 (en) 2008-07-07 2010-01-14 Oxford Nanopore Technologies Limited Base-detecting pore
EP2307540B1 (en) 2008-07-07 2017-04-19 Oxford Nanopore Technologies Limited Enzyme-pore constructs
GB0820927D0 (en) 2008-11-14 2008-12-24 Isis Innovation Method
CN101418290A (zh) * 2008-12-02 2009-04-29 中山大学 一种高效的elp融合蛋白酶及其制备和应用
US8214916B2 (en) 2009-01-26 2012-07-03 Nanoink, Inc. Large area, homogeneous array fabrication including leveling with use of bright spots
KR20110125226A (ko) * 2009-01-30 2011-11-18 옥스포드 나노포어 테크놀로지즈 리미티드 혼성화 링커
JP5843614B2 (ja) 2009-01-30 2016-01-13 オックスフォード ナノポア テクノロジーズ リミテッド 膜貫通配列決定における核酸構築物のためのアダプター
GB0905140D0 (en) 2009-03-25 2009-05-06 Isis Innovation Method
WO2010124180A1 (en) * 2009-04-23 2010-10-28 Phasebio Pharmaceuticals, Inc. Phenylalanine hydroxylase fusion protein and methods for treating phenylketonuria
EP3311828B1 (en) * 2009-08-14 2021-04-07 Phasebio Pharmaceuticals, Inc. Modified vasoactive intestinal peptides
US8940868B2 (en) * 2009-10-08 2015-01-27 The General Hospital Corporation Elastin based growth factor delivery platform for wound healing and regeneration
US9035028B2 (en) * 2010-03-10 2015-05-19 Emory University Temperature sensitive conjugate compositions
US9290794B2 (en) 2010-05-11 2016-03-22 Promega Corporation Mutant protease biosensors with enhanced detection characteristics
EP2990479B1 (en) 2010-05-11 2019-03-27 Promega Corporation Mutant protease biosensors with enhanced detection characteristics
CN101955960B (zh) * 2010-08-03 2012-05-23 中山大学 一种利用类弹性蛋白标签纯化重组乳糖酶的方法
CA2827170A1 (en) 2011-02-11 2012-08-16 David M. Hilbert Monovalent and multivalent multispecific complexes and uses thereof
CN103460040B (zh) 2011-02-11 2016-08-17 牛津纳米孔技术有限公司 突变型孔
ES2669190T3 (es) 2011-06-06 2018-05-24 Phasebio Pharmaceuticals, Inc. Uso de péptidos intestinales vasoactivos modificados en el tratamiento de la hipertensión
CN102241747A (zh) * 2011-06-17 2011-11-16 李立文 类人弹性蛋白及其生产方法
IN2014DN00221A (OSRAM) 2011-07-25 2015-06-05 Oxford Nanopore Tech Ltd
US9102763B2 (en) 2011-07-26 2015-08-11 University Of Southern California Controlled release of ocular biopharmaceuticals using bioresponsive protein polymers
JP6169079B2 (ja) * 2011-08-24 2017-07-26 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 徐放のための活性剤の製剤
CA2875983A1 (en) * 2012-02-08 2013-08-15 Seneb Biosciences, Inc. Treatment of hypoglycemia
US20130210747A1 (en) 2012-02-13 2013-08-15 University Of Southern California Methods and Therapeutics Comprising Ligand-Targeted ELPs
JP6157877B2 (ja) * 2012-02-28 2017-07-05 三洋化成工業株式会社 組織再生用ゲル、組織再生用タンパク質溶液及び組織再生用ゲルの製造方法
KR102083695B1 (ko) 2012-04-10 2020-03-02 옥스포드 나노포어 테크놀로지즈 리미티드 돌연변이체 리세닌 기공
WO2014013259A1 (en) 2012-07-19 2014-01-23 Oxford Nanopore Technologies Limited Ssb method
WO2014026054A2 (en) 2012-08-10 2014-02-13 University Of Southern California CD20 scFv-ELPs METHODS AND THERAPEUTICS
WO2014028776A1 (en) * 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
EP2945643A4 (en) * 2013-01-15 2017-04-26 Phasebio Pharmaceuticals, Inc. Therapeutic agents, compositions, and methods for glycemic control
GB201314695D0 (en) 2013-08-16 2013-10-02 Oxford Nanopore Tech Ltd Method
EP2964779B1 (en) 2013-03-08 2018-08-29 Oxford Nanopore Technologies Limited Use of spacer elements in a nucleic acid to control movement of a helicase
GB201313477D0 (en) 2013-07-29 2013-09-11 Univ Leuven Kath Nanopore biosensors for detection of proteins and nucleic acids
WO2015051001A2 (en) * 2013-10-01 2015-04-09 University Of Mississippi Medical Center Composition and method for therapeutic agent delivery during pregnancy
US11268127B2 (en) 2014-02-04 2022-03-08 Duke University Systems and devices for protease detection based on engineered polymers and biopolymers and methods of use
GB201403096D0 (en) 2014-02-21 2014-04-09 Oxford Nanopore Tech Ltd Sample preparation method
ES2879804T3 (es) 2014-04-21 2021-11-23 D&D Pharmatech Inc Agonistas del receptor de TRAIL para el tratamiento de enfermedades fibróticas
CN106459159B (zh) 2014-05-02 2021-11-30 牛津纳米孔技术公司 突变孔
CA2947982C (en) 2014-05-08 2022-11-29 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
US10400014B2 (en) 2014-09-01 2019-09-03 Oxford Nanopore Technologies Ltd. Mutant CsgG pores
WO2016055778A1 (en) 2014-10-07 2016-04-14 Oxford Nanopore Technologies Limited Mutant pores
GB201418159D0 (en) 2014-10-14 2014-11-26 Oxford Nanopore Tech Ltd Method
WO2016081884A2 (en) 2014-11-21 2016-05-26 Phasebio Pharmaceuticals, Inc. Elp fusion proteins for controlled and sustained release
EP3229845B1 (en) 2014-12-10 2020-05-27 University of Southern California Generation of hemoglobin-based oxygen carriers using elastin-like polypeptides
CN107427556B (zh) 2015-02-09 2022-02-25 费斯生物制药公司 用于治疗肌肉疾病和病症的方法和组合物
WO2017020025A1 (en) * 2015-07-29 2017-02-02 Kiick Kristi Thermoresponsive bioconjugates and their controlled delivery of cargo
CN106632682A (zh) * 2015-08-04 2017-05-10 清华大学 融合蛋白ifn-elp及其应用
WO2017024182A1 (en) 2015-08-04 2017-02-09 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
KR101759122B1 (ko) 2015-08-07 2017-07-18 계명대학교 산학협력단 오렉신 a를 함유하는 당뇨병 치료용 약학 조성물
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
CN109195620B (zh) 2016-04-07 2022-06-28 约翰霍普金斯大学 用死亡受体激动剂治疗胰腺炎和疼痛的组合物和方法
KR102646323B1 (ko) * 2016-05-06 2024-03-13 이뮤노포지 주식회사 제어된 지속 방출을 위한 elp 융합 단백질
GB201609220D0 (en) 2016-05-25 2016-07-06 Oxford Nanopore Tech Ltd Method
US11467156B2 (en) 2016-06-01 2022-10-11 Duke University Nonfouling biosensors
CN107459580A (zh) * 2016-06-06 2017-12-12 易金阳 一种利用酵母菌表达含有穿膜肽的寡肽‑1（egf）创新制备工艺
RU2019110848A (ru) 2016-09-14 2020-10-15 Дьюк Юниверсити Наночастицы на основе триблочных полипептидов для доставки гидрофильных лекарственных средств
JP2020500150A (ja) 2016-09-23 2020-01-09 デューク ユニバーシティ 下限臨界溶液温度挙動を有する非反復かつ非構造的ポリペプチド
CN106519040B (zh) * 2016-11-02 2020-03-27 南京大学 一种含肿瘤坏死因子相关凋亡诱导配体的融合蛋白和其制备方法及由该蛋白自组装的纳米粒
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
KR101955366B1 (ko) * 2017-06-02 2019-03-07 인제대학교 산학협력단 인터페론 베타-엘라스틴 재조합 단백질 및 이의 생산방법
WO2019006374A1 (en) 2017-06-30 2019-01-03 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS
JP7074995B2 (ja) * 2017-10-13 2022-05-25 林兼産業株式会社 線維芽細胞増殖促進剤及び線維芽細胞におけるエラスチン産生促進剤
WO2019147954A1 (en) 2018-01-26 2019-08-01 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
CN108531492A (zh) * 2018-04-23 2018-09-14 内蒙古农业大学 利用类弹性蛋白elp构建活性绵羊β-防御素sbd-1体外表达的方法
US12257308B2 (en) 2018-04-30 2025-03-25 Duke University Stimuli-responsive PEG-like polymer-based drug delivery platform
GB201807793D0 (en) 2018-05-14 2018-06-27 Oxford Nanopore Tech Ltd Method
US11649275B2 (en) 2018-08-02 2023-05-16 Duke University Dual agonist fusion proteins
WO2020037100A1 (en) 2018-08-16 2020-02-20 Isolere Bio, Inc. Genetically encoded polypeptide for affinity capture and purification of biologics
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
US20220289812A1 (en) * 2019-08-09 2022-09-15 Phasebio Pharmaceuticals, Inc. Elp fusion proteins comprising parathyroid hormone for controlled and sustained release
JP2023514611A (ja) * 2020-02-19 2023-04-06 アイソレア バイオ，インコーポレイテッド タンパク質ベースの精製マトリックス及びその使用方法
US20230128032A1 (en) 2020-03-31 2023-04-27 Curtails Llc Early Drug Interventions to Reduce COVID-19 Related Respiratory Distress, Need for Respirator Assist and Death
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
CA3179177A1 (en) 2020-12-23 2022-06-30 Jazz Pharmaceuticals Ireland Ltd. Methods of purifying charge-shielded fusion proteins
US20250368708A1 (en) * 2022-05-23 2025-12-04 Fudan University TREFOIL FACTOR 2/INTERFERON alpha2 FUSION PROTEIN AND APPLICATION THEREOF IN PREVENTION AND TREATMENT OF VIRAL INFECTIOUS DISEASES
CN115724915B (zh) * 2022-08-17 2025-08-12 上普博源（北京）生物科技有限公司 类弹性蛋白多肽粘合剂及其制备方法与应用
CN117777303A (zh) * 2022-09-27 2024-03-29 北京大学 一种高亲和力pd1蛋白偶联物及其应用
EP4644412A1 (en) * 2022-12-27 2025-11-05 NexThera Co., Ltd. Manufacture of elastin-like polypeptide-based recombinant protein and animal cell expression platform thereof
WO2025076213A1 (en) * 2023-10-04 2025-04-10 The Board Of Trustees Of The Leland Stanford Junior University Isothermally phase-separable elastin-like polypeptides, compositions, and methods of use thereof
WO2025100511A1 (ja) * 2023-11-10 2025-05-15 地方独立行政法人神奈川県立産業技術総合研究所 融合ペプチド

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE375393T1 (de) * 1998-01-30 2007-10-15 Asubio Pharma Co Ltd Verfahren zur herstellung eines peptids mittels eines hilfspeptids
US20050255554A1 (en) * 2000-03-20 2005-11-17 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
US6852834B2 (en) * 2000-03-20 2005-02-08 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
EP2275557A1 (en) * 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albumin fusion proteins
EP1355942B1 (en) * 2000-12-07 2008-08-27 Eli Lilly And Company Glp-1 fusion proteins
US20030098869A1 (en) * 2001-11-09 2003-05-29 Arnold Glenn Christopher Real time interactive video system
US20060130158A1 (en) * 2002-08-30 2006-06-15 Turner Andrew J Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
NZ543292A (en) * 2003-06-12 2008-04-30 Lilly Co Eli GLP-1 analog fusion proteins
JP4149867B2 (ja) * 2003-07-28 2008-09-17 キヤノンファインテック株式会社 プリンタ、その制御方法
US7019845B1 (en) * 2004-10-06 2006-03-28 Rudolph Technologies, Inc. Measuring elastic moduli of dielectric thin films using an optical metrology system
WO2006110292A2 (en) * 2005-03-25 2006-10-19 The Regents Of The University Of California Temperature-triggered immobilization and purification of antibodies

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170107352A (ko) * 2016-03-14 2017-09-25 한양대학교 에리카산학협력단 상 전이 거동을 가지는 폴리펩타이드, 상기 폴리펩타이드-칼모듈린-폴리펩타이드의 다중-자극 반응성을 가지는 삼중 블럭 폴리펩타이드, 상기 삼중 블럭 폴리펩타이드로 제조된 하이드로젤 및 상기 하이드로젤의 용도
KR101936470B1 (ko) * 2016-03-14 2019-01-17 한양대학교 에리카산학협력단 상 전이 거동을 가지는 폴리펩타이드, 상기 폴리펩타이드-칼모듈린-폴리펩타이드의 다중-자극 반응성을 가지는 삼중 블럭 폴리펩타이드, 상기 삼중 블럭 폴리펩타이드로 제조된 하이드로젤 및 상기 하이드로젤의 용도
KR20170114251A (ko) * 2016-03-24 2017-10-13 한양대학교 에리카산학협력단 지능형 약물 전달을 위한 다중 자극 반응성을 지닌 칼모듈린-엘라스틴 이중 블럭 폴리펩타이드의 동적 나노 전달체 및 제조방법
KR102028931B1 (ko) 2016-03-24 2019-10-08 한양대학교 에리카산학협력단 지능형 약물 전달을 위한 다중 자극 반응성을 지닌 칼모듈린-엘라스틴 이중 블럭 폴리펩타이드의 동적 나노 전달체 및 제조방법
KR20220026515A (ko) * 2020-08-25 2022-03-04 한양대학교 에리카산학협력단 자극 반응성 및 표면 부착성을 가진 점착성 엘라스틴 및 서커린 기반 다중 블록 코폴리펩타이드, 그의 자가조립 구조체 및 주사형 하이드로겔의 생접착제 응용
KR102687389B1 (ko) 2020-08-25 2024-07-25 한양대학교 에리카산학협력단 자극 반응성 및 표면 부착성을 가진 점착성 엘라스틴 및 서커린 기반 다중 블록 코폴리펩타이드, 그의 자가조립 구조체 및 주사형 하이드로겔의 생접착제 응용

Also Published As

Publication number Publication date
JP2010502734A (ja) 2010-01-28
IL197442A (en) 2015-04-30
CN101578373A (zh) 2009-11-11
WO2008030968A3 (en) 2008-11-13
CN103230598A (zh) 2013-08-07
AU2007292295A1 (en) 2008-03-13
AU2007292295B2 (en) 2013-06-06
CA2663047A1 (en) 2008-03-13
US20130143802A1 (en) 2013-06-06
MX2009002547A (es) 2009-06-19
JP2016026167A (ja) 2016-02-12
JP5802250B2 (ja) 2015-10-28
JP2014051510A (ja) 2014-03-20
IL197442A0 (en) 2011-08-01
WO2008030968A2 (en) 2008-03-13
EP2059606A4 (en) 2010-04-07
IL232825A0 (en) 2014-07-31
US20130178416A1 (en) 2013-07-11
EP2059606A2 (en) 2009-05-20
US20110039776A1 (en) 2011-02-17

Similar Documents

Publication Publication Date Title
JP5802250B2 (ja) 融合ペプチド治療用組成物
US11952432B2 (en) Cell-permeable stapled peptide modules for cellular delivery
KR101993714B1 (ko) 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
US20090220455A1 (en) Pharmaceutical compositions comprising elp fusion proteins
US20040197876A1 (en) Recombinant fusion proteins and the trimers thereof
KR20160013058A (ko) 암의 치료를 위한 방법 및 조성물
KR102623470B1 (ko) Bph 증상의 악화 또는 진행을 개선하거나 예방하는 방법
KR20120125455A (ko) 세포내 타겟 결합용 바이포달 펩타이드 바인더
KR20150079771A (ko) Rtrail 변이체 및 이의 모노메틸 오리스타틴 e 접합체
US5962634A (en) IgE antagonists
JP5416901B2 (ja) 興味のある分子の細胞内位置決めのためのベクターとして用いられるマウロカルシン由来ペプチド
KR20110139256A (ko) Ｓｐａｒｃ 혈관형성 영역과 사용방법
US11179444B2 (en) Glucagon analogs and methods of use thereof
EP2270055A2 (en) Cell-permeable endostatin recombinant protein, a polynucleotide encoding the same, and an anti-cancer preparation containing the same as an active component
WO2021072056A1 (en) P53 peptide disrupters of f0x04:p53 protein binding, variants and conjugates thereof.
AU2013224720B2 (en) Fusion peptide therapeutic compositions
WO2010138123A1 (en) P53 fusion proteins and methods of making and using thereof
US20250092120A1 (en) Anticancer peptide and use in treating cancer
Muttenthaler et al. Executive Guest Editor: Julio A. Camarero

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130322

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130627

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130924

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131018

R150 Certificate of patent or registration of utility model

Ref document number: 5395664

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250